BriaCell Therapeutics Corp. - 8-K Filing
BriaCell Therapeutics Corp. filed an 8-K on June 26, 2026, disclosing unaudited condensed interim consolidated financial statements for BriaPro Therapeutics Corp., its subsidiary, covering the three and nine months ended April 30, 2026. The filing includes a $712,236 comprehensive loss for the nine-month period ending April 30, 2026, with cash and equivalents of $299,950 as of that date. Additionally, BriaPro issued shares valued at $846,532 in connection with acquiring sCD80 license rights from its parent company. (Items: 7.01 Regulation FD Disclosure, 9.01 Condensed interim financial statements and Exhibits EXHIBIT INDEX Exhibit No)
Tickers: $BCTX